NCT06697938Recruiting
Neoadjuvant Chemoradiotherapy Compared to Neoadjuvant Chemotherapy for Luminal-Type Locally Advanced Breast Cancer: A Clinical Study
Source: ClinicalTrials.gov · Last updated 20 Nov 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This study focuses on preoperative treatment modalities for luminal-type locally advanced breast cancer. Based on modern precision radiotherapy technologies such as MRI-Linac, CyberKnife, and VMAT, it aims to compare the pCR rate, breast conserving surgery (BCS) rate, progression-free survival (PFS), and treatment-related side effects between preoperative neoadjuvant chemotherapy and preoperative neoadjuvant SBRT combined with chemotherapy in patients with this type of breast cancer. The goal is to provide new strategic options for the preoperative treatment of luminal-type locally advanced breast cancer.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 148 (estimated)
- First submitted
- 18 Nov 2024
- Start date
- 18 Nov 2024
- Primary completion date
- 31 Jul 2027
- Lead sponsor
- Sichuan Cancer Hospital and Research Institute
- Diseases
- Metastatic breast cancer
- NCT number
- NCT06697938
What you commit to
- Study type: Interventional
- Planned participants: 148
- From 18 Nov 2024 to the primary completion date, 31 Jul 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Active infection currently present; clinically evident heart disease; myocardial infarction or cerebrovascular accident within 6 months prior to enrollment.
Other illness
- History of malignancy at other sites, excluding curable non-melanoma skin cancer and carcinoma in situ of the cervix;
- Inflammatory breast cancer;
Other
- Inability to complete MRI;
- Bilateral or multifocal primary tumors;
Who the study is looking for
- Pathologically confirmed invasive breast cancer ;
- Breast MRI showing stages IIB to IIIC (2017 AJCC 8th edition staging);
- Clinical staging confirmed by chest MRI and/or axillary ultrasound, as well as CT scans of the neck, abdomen, and pelvis, and bone scintigraphy, including T and N staging and assessment of distant metastasis;
- Karnofsky performance score ≥80 or ECOG performance status of 0-1;
- No history of allergies to doxorubicin, cyclophosphamide, paclitaxel/docetaxel;
- No prior exposure to radiotherapy, chemotherapy, endocrine therapy, targeted therapy, or immunotherapy.
Age in the registry: 18 years to 70 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Sichuan Cancer Hospital Coordinator of this site? Confirm its status | Chengdu | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.